Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

Fox Chase Cancer Center News

August 17, 2021

Fox Chase Cancer Center Proudly Sponsors Miles for Melanoma Philadelphia 5K

PHILADELPHIA (August 17, 2021) - Fox Chase Cancer Center is proud to be a local sponsor and continued supporter of the annual Miles for Melanoma Philadelphia 5K, which will take place both in person and online this year.

August 13, 2021

Camille Ragin Appointed NIH Study Section Chair

PHILADELPHIA (August 13, 2021) – Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, has been appointed chair of the Cancer, Heart, and Sleep Epidemiology B Study Section, a committee that will review grant applications submitted to the National Institutes of Health (NIH).

August 12, 2021

Fox Chase Researcher Receives Funding From NCCN to Evaluate Drug in Gastric and Esophageal Cancer Patients

PHILADELPHIA (August 12, 2021) – Namrata “Neena” Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has received funding from the National Comprehensive Cancer Network (NCCN) to evaluate neratinib, also known by its brand name Nerlynx, in combination with another drug for the treatment of refractory gastric and esophageal cancer.

August 6, 2021

David S. Weinberg Named Co-Editor-in-Chief of Gastroenterology, American Gastroenterological Association’s Premier Journal

PHILADELPHIA (August 6, 2021)—David S. Weinberg, MD, MSc, chair of the Department of Medicine at Fox Chase Cancer Center, was recently named one of two new editors-in-chief of Gastroenterology.

July 23, 2021

Overall Rates of Reconstructive Breast Surgery for Women With Inflammatory Breast Cancer Undergoing Mastectomy Remain Low

PHILADELPHIA (July 23, 2021) – The percentage of inflammatory breast cancer (IBC) patients selecting reconstructive surgery after mastectomy, whether immediate or delayed, remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research.

July 23, 2021

Fox Chase Researchers Find Pak1 Gene Inhibition Reduces Tumor Size in Mice With Neurofibromatosis Type 2

PHILADELPHIA (July 23, 2021)—Researchers at Fox Chase Cancer Center recently conducted a mouse model study showing that tumor size can be reduced in cases of neurofibromatosis type 2 (NF2) by targeting PAK1, a gene that regulates cell motility and morphology. PAKs are members of the p21-activated kinase family represented by six genes (PAK1-6).

July 23, 2021

Weekly Outpatient Palliative Care Interventions Favored by Head and Neck Cancer Patients

PHILADELPHIA (July 23, 2021)—Over 90% of head and neck cancer patients found weekly palliative care visits to be a valuable addition to their treatment, a recent study conducted at Fox Chase Cancer Center has concluded.

July 23, 2021

New Web-Based Platform Addresses Quality of Life After Treatment for Prostate Cancer Survivors

PHILADELPHIA (July 23, 2021) – Although it improved certain aspects of adaptive coping among prostate cancer survivors, a small randomized, controlled trial found use of PROGRESS, a web-based intervention developed at Fox Chase Cancer Center, did not fully address coping and psychosocial demands. 

Pages

Connect with Fox Chase